HELICOBACTER PYLORI

HELICOBACTER PYLORI

Editorial:
SPRINGER
Año de edición:
Materia
Digestivo
ISBN:
978-4-431-55704-3
Páginas:
267
N. de edición:
1
Idioma:
Inglés
Ilustraciones:
43
Disponibilidad:
Disponible en 2-3 semanas

Descuento:

-5%

Antes:

145,59 €

Despues:

138,31 €

1. A Brief History of the Discovery of
2. Human Migration
3. CagA
4. Helicobacter Pylori VacA Exhibits Pleiotropic Actions in Host Cells
5. Autophagy
6. Ghrelin and Gut Hormone
7. Symptom Generation
8. Gastric Non-
9. Urea Breath Test and Rapid Urease Test
10. Endoscopic Findings of
11. Stratification of Gastric Cancer Risk by
12. Prevention of Gastric Cancer by
13. Trends in Global Eradication Rates
14. Personalized Therapy in
15. Quadruple Regimens for
16. Third-Line Eradication Therapy

This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP). Medical authorities worldwide now recommend a “test and treat” strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program.

This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.

Features
• Reviews the most recent pathogenetic, diagnostic, and therapeutic approaches in connection with Helicobacter pylori
• Maximizes reader insight into the trends in clinical practice to address Helicobacter pylori
• Provides comprehensive knowledge for treating Helicobacter pylori

Authors
• Dr Hidekazu Suzuki, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
• Dr Robin Warren, A winner of the 2005 Nobel Prize winner in Physiology or Medicine. Emeritus Professor at the University of Western Australia and the Royal Perth Hospital, Australia
• Dr Barry Marshall, A winner of the 2005 Nobel Prize winner in Physiology or Medicine. Marshall Centre for Infectious Diseases Research and Training, School of Pathology and Laboratory Medicine, The University of Western Australia, Australia